GLPwatch
Papers (10409)
Page 107 of 174, ranked by citation count.
- Activation of glucagon-like peptide-1 receptors and skilled reach foraging.
- Predictive factors associated with primary failure to exenatide and non goal attainment in patients with type 2 diabetes.
- Modeling potential cost-effectiveness of tirzepatide versus lifestyle modification for patients with overweight and obesity.
- GLP-1 Receptor Agonists Are Associated with Reduced Ascending Aorta Dilatation in Patients with Type 2 Diabetes: A Prospective Study.
- Tirzepatide for adults living with obesity.
- Testicular cytoprotective effect of glucagon like peptide-1 in diabetic rats involves inhibition of apoptosis, endoplasmic reticulum stress and activation of autophagy.
- GLP-1R agonist therapy and vaccine response: Neglected implications.
- Comparison of efficacy and safety of insulin degludec/liraglutide and insulin glargine U-100/lixisenatide in individuals with type 2 diabetes mellitus using professional continuous glucose monitoring.
- The Impact and Safety of GLP-1 Agents and Breast Cancer.
- The impact of GLP-1 receptor agonist shortages on glycaemic Control: Findings from an Australian specialist diabetes clinic.
- Efficacy and Safety of Oral Semaglutide in the Treatment of Type 2 Diabetes: A Meta-Analysis.
- Combination therapy of glucagon-like peptide-1 receptor agonists and insulin for patients who developed diabetes after partial pancreatectomy.
- Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity.
- Acute Pancreatitis Caused by Tirzepatide.
- Comparative efficacy and safety of weekly tirzepatide versus weekly insulin in type 2 diabetes: A network meta-analysis of randomized clinical trials.
- Patients With Severe Obesity Are Made Eligible for Complex Abdominal Wall Repair After Preoptimization With GLP-1 Agonists: Results of a Bicentric Pilot Study.
- Managing Diabetes and Preventing Heart Disease: Have We Found a Safe and Effective Agent?
- Genetic predictors of GLP1 receptor agonist weight loss and side effects.
- Short-Term Effectiveness and Reduction in Insulin Requirements in Patients With Type 2 Diabetes Treated With IdegLira in a Real-World Setting.
- Are glucagon-like peptide-1 receptor agonists anti-consummatory drugs?
- Eosinophilic Panniculitis Following the Subcutaneous Injection of Exenatide Extended-Release.
- Heterogeneity of Treatment Effects of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss in Adults: A Systematic Review and Meta-Analysis.
- Should tirzepatide be considered for early management in type 2 diabetes? Pros and cons.
- Cardiovascular effects of tirzepatide.
- The Effectiveness and Value of Oral Semaglutide for Type 2 Diabetes Mellitus.
- Glucagon-Like Peptide-1 Receptor Agonists-How Safe Are They?
- Improved HbA1c and Body Weight in GADA-Positive Individuals Treated With Tirzepatide: A Post Hoc Analysis of SURPASS.
- GLP1 and GIP Receptor Agonists: Effects on the Gastrointestinal Tract and Management Strategies for Primary Care Physicians.
- Comparison of insulin degludec (IDeg)/insulin Aspart (IAsp) co-formulation therapy twice-daily with free combination of GLP-1 receptor agonist liraglutide plus insulin degludec in Tochigi: IDEAL Trial.
- Safety and Efficacy of Tirzepatide in Solid-Organ Transplant Recipients: Experience of a Quaternary Care Center in the Middle East.
- Does glucose-dependent insulinotropic polypeptide receptor blockade as well as agonism have a role to play in management of obesity and diabetes?
- iGlarLixi provides a higher derived time-in-range versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with type 2 diabetes: A post hoc analysis.
- Liraglutide intervention improves high-glucose-induced reactive gliosis of Müller cells and ECM dysregulation.
- Tirzepatide Versus Semaglutide for Weight Loss in Overweight and Obese Adults: A Systematic Review and Meta-Analysis of Direct Comparative Studies.
- Impact of a pharmacist-led weight management service in a cardiology clinic.
- Real-world use of tirzepatide among individuals without evidence of type 2 diabetes: Results from the Veradigm® database.
- A novel therapeutic prospect: a dual-acting tirzepatide for Alzheimer's disease.
- Incretin attenuates diabetes-induced damage in rat cardiac tissue.
- Addition of exenatide BID to insulin glargine: a post-hoc analysis of the effect on glycemia and weight across a range of insulin titration.
- Effect of acute treatment with the glucagon-like peptide-1 receptor agonist, liraglutide, and estrus phase on cue- and drug-induced fentanyl seeking in female rats.
- The limitation of lipidation: Conversion of semaglutide from once-weekly to once-monthly dosing.
- A <u>r</u>andomis<u>e</u>d, controlled, double blind <u>s</u>tudy to assess mechan<u>i</u>stic effects of combination therapy of dapag<u>li</u>flozin with <u>e</u>xenatide QW versus dapagliflozin alone i<u>n</u> obese patients with <u>t</u>ype 2 diabetes mellitus (RESILIENT): study protocol.
- Tirzepatide to treat obesity: phase III results.
- Liraglutide-associated depression in a patient with type 2 diabetes: A case report and discussion.
- Efficacy and Safety of GLP- 1 Receptor Agonists in the Management of Weight Recurrence or Suboptimal Clinical Response after Undergoing Metabolic Bariatric Surgeries: A Meta-Analysis.
- Exenatide Once Weekly in the Treatment of Patients with Multiple System Atrophy.
- GZR18, a novel long-acting GLP-1 analog, demonstrated positive in vitro and in vivo pharmacokinetic and pharmacodynamic characteristics in animal models.
- Hearing protection and damage mitigation in Chinchillas exposed to repeated low-intensity blasts.
- Long-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the US.
- Generalizability of the Results of Cardiovascular Outcome Trials of Glucagon-Like Peptide 1 Receptor Agonists in Chinese Patients with Type 2 Diabetes Mellitus.
- Cardiovascular event reduction among a US population eligible for semaglutide per the SELECT trial.
- The Synthesis of SNAC Phenolate Salts and the Effect on Oral Bioavailability of Semaglutide.
- Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine.
- Psychiatric adverse events linked to glucagon-like peptide 1 analogues: a disproportionality analysis in American, Canadian and Australian adverse event databases.
- Role of incretin-based therapies and sodium-glucose co-transporter-2 inhibitors as adjuncts to insulin therapy in Type 2 diabetes, with special reference to IDegLira.
- Characterization of glucagon-like peptide-1 (GLP-1) agonist exposures reported to a single United States poison center.
- The role of glucagon-like peptide-1 receptor agonists in nonalcoholic fatty liver disease.
- Rational combination therapy for type 2 diabetes.
- Linearity of β-cell response across the metabolic spectrum and to pharmacology: insights from a graded glucose infusion-based investigation series.
- Pharmacotherapy for obstructive sleep apnea: a critical review of randomized placebo-controlled trials.